{"id":10395,"date":"2021-06-15T08:49:43","date_gmt":"2021-06-15T15:49:43","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=10395"},"modified":"2021-06-16T09:13:38","modified_gmt":"2021-06-16T16:13:38","slug":"covid-19-literature-situation-report-june-15-2021","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/06\/15\/covid-19-literature-situation-report-june-15-2021\/","title":{"rendered":"COVID-19 Literature Situation Report June 15, 2021"},"content":{"rendered":"<p>The scientific literature on COVID-19 is rapidly evolving and these articles were selected for review based on their relevance to Washington State decision making around COVID-19 response efforts. Included in these Lit Reps are some manuscripts that have been made available online as pre-prints but have not yet undergone peer review. Please be aware of this when reviewing articles included in the Lit Reps.<\/p>\n<p><em>Today&#8217;s summary is based on a review of 486 articles (469 published, 17 in preprint)<\/em><\/p>\n<p><strong><a href=\"https:\/\/depts.washington.edu\/pandemicalliance\/wordpress\/wp-content\/uploads\/2021\/06\/LitRep_20210610.docx.pdf\">View the PDF version here.<\/a><\/strong><\/p>\n<h2>Key Takeaways<\/h2>\n<ul>\n<li style=\"font-weight: 400\"><b>The incidence of all-cause mortality among residents of assisted living settings in the US between January and August 2020 was 17% higher compared to the same time period in 2019. Among the 10 states with the highest COVID-19 community spread, during that time period the incidence of all-cause mortality was 24% higher. <\/b><a href=\"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.13411\"><span style=\"font-weight: 400\">More<\/span><\/a><\/li>\n<li style=\"font-weight: 400\"><b>COVID-19 vaccination among pregnant women was lowest among those aged 18-24 years (6%) and among Hispanic (12%) and Black women (6%) out of 22,197 pregnant women in the US identified in CDC&#8217;s Vaccine Safety Data Link as of May 8, 2021. Of those initiating vaccination 68% had completed either a 1- or 2-dose series.<\/b> <a href=\"https:\/\/doi.org\/10.15585\/mmwr.mm7024e2\"><span style=\"font-weight: 400\">More<\/span><\/a><\/li>\n<li style=\"font-weight: 400\"><b>A third dose of a COVID-19 mRNA vaccine received a median of 67 days after the second dose was not able to elicit detectable anti-SARS-CoV-2 antibody responses in 53% of a cohort of solid organ transplant recipients (n=30). Prior to the third dose, 80% of participants did not have detectable antibody responses after completing the 2-dose vaccination series. <\/b><a href=\"https:\/\/doi.org\/10.7326\/L21-0282\"><span style=\"font-weight: 400\">More<\/span><\/a><\/li>\n<li style=\"font-weight: 400\"><b>SARS-CoV-2 infections caused by the B.1.617.2 (Delta) variant of concern were at increased risk of hospitalization (HR=1.9) compared to the B.1.1.7 (Alpha) variant, according to a whole population cohort study in Scotland, where the B.1.617.2 (Delta) has become the dominant variant. Estimated vaccine effectiveness 14 days after the second dose against infection was reduced against B.1.617.2 (Delta) compared to B.1.1.7 (Alpha) for the Pfizer-BioNTech (92% vs 79%) and Oxford-AstraZeneca vaccine (73% vs 60%). <\/b><a href=\"https:\/\/doi.org\/10.1016\/S0140-6736(21)01358-1\"><span style=\"font-weight: 400\">More<\/span><\/a><\/li>\n<\/ul>\n<div id=\"uw-accordion-shortcode\">\n<h3>Article Summaries<\/h3>\n<div class=\"js-accordion\" data-accordion-prefix-classes=\"uw-accordion-shortcode\">\n<div class=\"js-accordion__panel\" >\n<h2 class=\"js-accordion__header\"><span style=\"font-weight: 400\">Geographic Spread<\/span><\/h2>\n<div class=\"su-posts su-posts-default-loop\">\n<div id=\"su-post-10399\" class=\"su-post\">\n<h5 class=\"su-post-title\">Antibodies to SARS-CoV-2 in All of Us Research Program Participants, January 2-March 18, 2020<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">SARS-CoV-2 antibodies were detected in persons from diverse geographic regions in the US prior to the first syndromic cases identified by PCR, according to analysis of samples collected as part of the <\/span><i><span style=\"font-weight: 400\">All of Us <\/span><\/i><span style=\"font-weight: 400\">study. The<\/span><i><span style=\"font-weight: 400\"> All of Us<\/span><\/i><span style=\"font-weight: 400\"> study was started in 2018 and has enrolled a diverse population of US adults from all 50 states. Participation in the study includes repeated collection of blood samples. Using a two-tiered serologic testing algorithm to define seropositive individuals (positive on Abbott with subsequent seropositive on EURUOIMMUN), the authors reanalyzed serum specimens from January to March 2020 and determined that SARS-CoV-2 may have been circulating in Illinois, Wisconsin and Massachusetts as early as January 2020.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Althoff et al. (June 15, 2021). Antibodies to SARS-CoV-2 in All of Us Research Program Participants, January 2-March 18, 2020. Clinical Infectious Diseases. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1093\/cid\/ciab519\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1093\/cid\/ciab519<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-10397\" class=\"su-post\">\n<h5 class=\"su-post-title\">Rapidly Emerging SARS-CoV-2 B.1.1.7 Sub-Lineage in the United States of America with Spike Protein D178H and Membrane Protein V70L Mutations<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Genomic surveillance of SARS-CoV-2 cases identified an expanding US-specific sub-lineage of the B.1.1.7 (Alpha) variant. This sub-lineage is characterized with sequential acquisition of a membrane protein mutation, V20L, in November 2020 and a spike mutation, D178H, in early February 2021. The proportion of B.1.1.7 (Alpha) isolates in the US belonging to this sub-lineage increased from 0.15% in February to 1.8% in April 2021. The sub-lineage comprises 37% of B.1.1.7 (Alpha) isolates in Washington State to date and has also been detected in 30 other states. Phylogenetic analysis suggests the sub-lineage may have originated from either California or Washington, while structural analysis suggests the D178H mutation may affect neutralization capacity of antibodies targeting the N terminal domain. <\/span><i><span style=\"font-weight: 400\">[EDITORIAL NOTE: A pre-print version of this article was summarized in this report on May 19, 2021.]<\/span><\/i><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Shen et al.\u00a0(June 14, 2021). Rapidly Emerging SARS-CoV-2 B.1.1.7 Sub-Lineage in the United States of America with Spike Protein D178H and Membrane Protein V70L Mutations. Emerging Microbes &amp; Infections. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1080\/22221751.2021.1943540\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1080\/22221751.2021.1943540<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"js-accordion__panel\" >\n<h2 class=\"js-accordion__header\"><span style=\"font-weight: 400\">Testing and Treatment<\/span><\/h2>\n<div class=\"su-posts su-posts-default-loop\">\n<div id=\"su-post-10401\" class=\"su-post\">\n<h5 class=\"su-post-title\">SARS-CoV -2 Antibody Persistence in COVID-19 Convalescent Plasma Donors: Dependency on Assay Format and Applicability to Serosurveillance<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">SARS-CoV-2 antibody responses were shown to increase over time in a study of plasma collected up to 63-129 days following symptom resolution from 18 patients recovered from COVID-19 when using direct double Ag-sandwich assays (Ortho Total Ig and Roche Total Ig). By contrast, measurements from indirect binding assays showed a declining antibody response. Due to their stability over time, the authors suggest using direct double sandwich assays for serosurveillance studies.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Di Germanio et al.\u00a0(June 14, 2021). SARS-CoV -2 Antibody Persistence in COVID-19 Convalescent Plasma Donors: Dependency on Assay Format and Applicability to Serosurveillance. Transfusion. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1111\/trf.16555\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1111\/trf.16555<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"js-accordion__panel\" >\n<h2 class=\"js-accordion__header\">Vaccines and Immunity<\/h2>\n<div class=\"su-posts su-posts-default-loop\">\n<div id=\"su-post-10413\" class=\"su-post\">\n<h5 class=\"su-post-title\">Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">In solid organ transplant recipients, a third dose of a COVID-19 vaccine was not able to elicit detectable anti-SARS-CoV-2 antibody responses in 53% of participants in a cohort study (n=30). Prior to receiving the third dose, 80% of patients did not have detectable antibody responses. All patients were fully vaccinated with mRNA vaccines (57% Pfizer-BioNTech, 43% Moderna), and received the third dose after a median of 67 days (50% Johnson &amp; Johnson-Janssen, 30% Moderna, 20% Pfizer-BioNTech). Participants were assessed for an antibody response after a median of 14 days after the third vaccination.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Werbel et al.\u00a0(June 15, 2021). Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Annals of Internal Medicine. <\/span><\/i><a href=\"https:\/\/doi.org\/10.7326\/L21-0282\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.7326\/L21-0282<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-10411\" class=\"su-post\">\n<h5 class=\"su-post-title\">Naturally Enhanced Neutralizing Breadth against SARS-CoV-2 One Year after Infection<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">82% of individuals recovered from COVID-19 maintained RBD-specific IgG titers, RBD-specific B cells, and neutralizing activities between 6-12 months after infection, according to analysis of 68 recovered individuals, suggesting long-lived immunity to COVID-19. In 41% of participants who received an mRNA vaccine, vaccination increased IgG responses by 30-fold, neutralizing activity by 50-fold, and circulating number of memory B cells by 9-fold. Sera from vaccinated individuals also showed robust neutralizing activity against variants of concern and neutralization breadth (the ability to neutralize a diverse panel of viruses) increased over time.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Wang et al.\u00a0(June 14, 2021). Naturally Enhanced Neutralizing Breadth against SARS-CoV-2 One Year after Infection. Nature. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1038\/s41586-021-03696-9\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1038\/s41586-021-03696-9<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-10409\" class=\"su-post\">\n<h5 class=\"su-post-title\">Allergic Symptoms after mRNA COVID-19 Vaccination and Risk of Incomplete Vaccination<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Self-reported allergic symptoms following the first dose of a COVID-19 mRNA vaccine was associated with a 5-fold increase in odds of not completing the second dose after adjusting for demographics, vaccine manufacturer, wave of vaccine eligibility, and other confounders in a prospective cohort of healthcare employees in Boston. Among 61,057 employees who received a first dose, incomplete vaccination occurred in 3% (43 of 1,261) of those who self-reporting allergic symptoms compared to 0.6% of those who did not report allergic symptoms. Self-reported severe allergic symptoms were rare (n=6) and associated with markedly increased odds of not completing the vaccination course (aOR=23).<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Robinson et al.\u00a0(June 11, 2021). Allergic Symptoms after mRNA COVID-19 Vaccination and Risk of Incomplete Vaccination. The Journal of Allergy and Clinical Immunology: In Practice. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1016\/j.jaip.2021.05.031\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1016\/j.jaip.2021.05.031<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-10407\" class=\"su-post\">\n<h5 class=\"su-post-title\">COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy \u2014 Eight Integrated Health Care Organizations, United States, December 14, 2020\u2013May 8, 2021<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">As of May 8, 2021, 16% (22,197 of 135,968) of pregnant women identified in CDC\u2019s Vaccine Safety Datalink, which includes integrated health systems from 7 US states, have received \u22651 dose of a COVID-19 vaccine during pregnancy. Of those initiating vaccination 68% have completed either a 1- or 2-dose series. Vaccination during pregnancy was highest among women aged 35-49 years (23%) and lowest among those aged 18-24 years (6%), and higher among Asian (25%) and white women (20%) compared to Hispanic (12%) and Black women (6%).<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Razzaghi et al.\u00a0(June 15, 2021). COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy \u2014 Eight Integrated Health Care Organizations, United States, December 14, 2020\u2013May 8, 2021. MMWR. <\/span><\/i><a href=\"https:\/\/doi.org\/10.15585\/mmwr.mm7024e2\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.15585\/mmwr.mm7024e2<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-10405\" class=\"su-post\">\n<h5 class=\"su-post-title\">Young Infants Exhibit Robust Functional Antibody Responses and Restrained IFN-\u03b3 Production to SARS-CoV-2<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">A study evaluating the immune responses in four infants with mild COVID-19 (median age 7 weeks old) found that compared to their parents who also had COVID-19 (n=8) and a cohort of adult controls with prior COVID-19 (n=10), infants had higher anti-SARS-CoV-2 IgG antibody levels in both sera and saliva and exhibited more robust serum neutralizing activity. Infants also had reduced production of interferon-gamma after direct <\/span><i><span style=\"font-weight: 400\">ex-vivo<\/span><\/i><span style=\"font-weight: 400\"> stimulation (ELISPOT), despite a comparable frequency of SARS-specific T cells and comparable capacity for expansion with prolonged stimulation with SARS-CoV-2 antigens.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Goenka et al.\u00a0(June 9, 2021). Young Infants Exhibit Robust Functional Antibody Responses and Restrained IFN-\u03b3 Production to SARS-CoV-2. Cell Reports Medicine. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1016\/j.xcrm.2021.100327\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1016\/j.xcrm.2021.100327<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-10403\" class=\"su-post\">\n<h5 class=\"su-post-title\">SARS-CoV-2 Delta VOC in Scotland: Demographics, Risk of Hospital Admission, and Vaccine Effectiveness<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">SARS-CoV-2 infections caused by the B.1.617.2 (Delta) variant of concern were at increased risk of hospitalization (HR=1.9) compared to the B.1.1.7 (Alpha) variant after adjusting for demographics, temporal trends, and comorbidities, according to an analysis of 19,543 confirmed infections and 377 hospitalizations in Scotland from April 1 to June 6, 2021. Considering the whole population cohort, estimated vaccine effectiveness 14 days after the second dose against infection was reduced against B.1.617.2 (Delta) compared to B.1.1.7 (Alpha) for the Pfizer-BioNTech (92% vs 79%) and Oxford-AstraZeneca vaccine (73% vs 60%).<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Sheikh et al.\u00a0(June 15, 2021). SARS-CoV-2 Delta VOC in Scotland: Demographics, Risk of Hospital Admission, and Vaccine Effectiveness. The Lancet. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1016\/S0140-6736(21)01358-1\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1016\/S0140-6736(21)01358-1<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"js-accordion__panel\" >\n<h2 class=\"js-accordion__header\"><span style=\"font-weight: 400\">Clinical Characteristics and Health Care Setting<\/span><\/h2>\n<div class=\"su-posts su-posts-default-loop\">\n<div id=\"su-post-10415\" class=\"su-post\">\n<h5 class=\"su-post-title\">Persistent COVID-19 Symptoms Are Highly Prevalent 6 Months after Hospitalization: Results from a Large Prospective Cohort<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Nearly 1 in 4 individuals hospitalized for COVID-19 had 3 or more persistent symptoms 6 months after hospital admission in a cohort study in France (n=1,137). Presence of 3 or more symptoms at 6 months was more common among women, those with 3 or more symptoms at admission, and those who were admitted to the ICU, but was not associated with age or having two or more comorbidities. At least one symptom was present in 68% of patients at 3-months and 60% at 6-month of follow-up, with fatigue, shortness of breath, joint pain, and muscle pain being the most common symptoms.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Ghosn et al.\u00a0(May 10, 2021). Persistent COVID-19 Symptoms Are Highly Prevalent 6 Months after Hospitalization: Results from a Large Prospective Cohort. Clinical Microbiology and Infection. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1016\/j.cmi.2021.03.012\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1016\/j.cmi.2021.03.012<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"js-accordion__panel\" >\n<h2 class=\"js-accordion__header\"><span style=\"font-weight: 400\">Mental Health and Personal Impact<\/span><\/h2>\n<div class=\"su-posts su-posts-default-loop\">\n<div id=\"su-post-10417\" class=\"su-post\">\n<h5 class=\"su-post-title\">SARS-CoV-2 Infection and Associated Rates of Diabetic Ketoacidosis in a New York City Emergency Department<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Emergency department (ED) visits resulting in a diagnosis for diabetic ketoacidosis (DKA) during early COVID-19 pandemic period of March to May 2020 were 70% higher than in the same period in 2019 in New York City (214 vs 106 diagnoses) according to an analysis of ED data extracted for routine quality review. By contrast, Total volume of ED visits declined by 27% from 2019 to 2020 (93,218 vs 59,009 visits).<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Ditkowsky et al.\u00a0(June 9, 2021). SARS-CoV-2 Infection and Associated Rates of Diabetic Ketoacidosis in a New York City Emergency Department. Western Journal of Emergency Medicine. <\/span><\/i><a href=\"https:\/\/doi.org\/10.5811\/westjem.2021.2.49634\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.5811\/westjem.2021.2.49634<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"js-accordion__panel\" >\n<h2 class=\"js-accordion__header\"><span style=\"font-weight: 400\">Public Health Policy and Practice<\/span><\/h2>\n<div class=\"su-posts su-posts-default-loop\">\n<div id=\"su-post-10423\" class=\"su-post\">\n<h5 class=\"su-post-title\">Estimation of Excess Mortality Rates Among US Assisted Living Residents During the COVID-19 Pandemic<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Incidence of all-cause mortality among a cohort of US Medicare beneficiaries residing in assisted living settings between January to August 2020 (n=425,333) was 17% higher compared to a cohort from the same time in 2019 (n=422,262). The incidence ratio was 36% higher during the peak week in April 8-14, 2020 (3.3 vs 2.2 deaths per 1,000 residents). Among the 10 states with the highest COVID-19 community spread during the study period, the incidence of all-cause mortality was 24% higher and up to 73% higher during the peak week.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Thomas et al.\u00a0(June 14, 2021). Estimation of Excess Mortality Rates Among US Assisted Living Residents During the COVID-19 Pandemic. JAMA Network Open. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.13411\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.13411<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-10421\" class=\"su-post\">\n<h5 class=\"su-post-title\">Comparable Seasonal Pattern for COVID-19 and Flu-like Illnesses<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">COVID-19 transmission was correlated with season in a manner similar to influenza-like illnesses (ILI), according to a comparison between the average annual time-series for ILIs based on incidence data from 2016 till 2019 and two COVID-19 time-series during 2020\/2021 in the Netherlands. The authors suggest that the high correlation seems to imply factors driving seasonality of ILIs, such as temperature, relative humidity, and seasonal allergens may also drive COVID-19 seasonality.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Hoogeveen and Hoogeveen. (June 8, 2021). Comparable Seasonal Pattern for COVID-19 and Flu-like Illnesses. One Health. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1016\/j.onehlt.2021.100277\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1016\/j.onehlt.2021.100277<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-10419\" class=\"su-post\">\n<h5 class=\"su-post-title\">COVID-19 and Telehealth Operations in Texas Primary Care Clinics: Disparities in Medically Underserved Area Clinics<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Texas clinics in medically underserved areas (MUAs) were less likely to conduct greater than half of their visits via telehealth compared to non-MUA clinics, according to an analysis of 1,344 pooled responses from Texas primary care providers between March 27 and May 22, 2020. Restricting the analysis to responses obtained after May 1, 2020 showed that the association had attenuated, suggesting that initial telehealth barriers among MUA clinics may have resolved over time.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Adepoju et al.\u00a0(May 2021). COVID-19 and Telehealth Operations in Texas Primary Care Clinics: Disparities in Medically Underserved Area Clinics. Journal of Health Care for the Poor and Underserved. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1353\/hpu.2021.0073\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1353\/hpu.2021.0073<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>Other Resources and Commentaries<\/h2>\n<ul>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1016\/j.heliyon.2021.e07233\"><span style=\"font-weight: 400\">Innovative Human Resource Management Strategies during the COVID-19 Pandemic: A Systematic Narrative Review Approach<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Heliyon (June)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1016\/j.jeoa.2021.100328\"><span style=\"font-weight: 400\">The Economic Burden of COVID-19 in the United States: Estimates and Projections under an Infection-Based Herd Immunity Approach<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Journal of the Economics of Ageing (May)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1016\/j.jhin.2021.06.002\"><span style=\"font-weight: 400\">Efficiency of Air Circulation Decontamination Device for Microorganisms Using Ultraviolet Radiation<\/span><\/a><span style=\"font-weight: 400\"> \u2013 The Journal of Hospital Infection (June)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.34172\/ijhpm.2021.57\"><span style=\"font-weight: 400\">Vaccine Inequities, Intellectual Property Rights and Pathologies of Power in the Global Response to COVID-19<\/span><\/a><span style=\"font-weight: 400\"> \u2013 International Journal of Health Policy and Management (May 26)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1016\/S2213-2600(21)00234-4\"><span style=\"font-weight: 400\">SARS-CoV-2 Antigen Testing: Weighing the False Positives against the Costs of Failing to Control Transmission<\/span><\/a><span style=\"font-weight: 400\"> \u2013 The Lancet Respiratory Medicine (June 15)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1101\/2021.06.10.21255008\"><span style=\"font-weight: 400\">Patient Outcomes and Lessons-Learned from Treating Patients with Severe COVID-19 at a Long-Term Acute Care Hospital<\/span><\/a><span style=\"font-weight: 400\"> \u2013 MedRxiv (June 14)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1016\/j.pedhc.2021.03.004\"><span style=\"font-weight: 400\">The Effect of COVID-19 Pandemic Restrictions on Lead Screening in a Primary Care Clinic<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Journal of Pediatric Health Care (May)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.7326\/M21-0319\"><span style=\"font-weight: 400\">Optimizing SARS-CoV-2 Surveillance in the United States: Insights From the National Football League Occupational Health Program<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Annals of Internal Medicine (June)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1016\/j.eclinm.2021.100904\"><span style=\"font-weight: 400\">COVID-19 and Migrant and Refugee Health: A Pointer to System Competence in Future Pandemic Preparedness<\/span><\/a><span style=\"font-weight: 400\"> \u2013 EClinicalMedicine (June)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.2196\/26242\"><span style=\"font-weight: 400\">Neighborhood Broadband and Use of Telehealth Among Older Adults: Cross-Sectional Study of National Survey Data Linked With Census Data<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Journal of Medical Internet Research (June 14)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1016\/j.annemergmed.2021.04.026\"><span style=\"font-weight: 400\">The Effect of the COVID-19 Pandemic on the Economics of United States Emergency Care<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Annals of Emergency Medicine (Apr)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1016\/j.animal.2021.100272\"><span style=\"font-weight: 400\">Review: SARS-CoV-2 Infection in Farmed Minks &#8211; an Overview of Current Knowledge on Occurrence, Disease and Epidemiology<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Animal (June)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1056\/NEJMc2108620\"><span style=\"font-weight: 400\">Delayed Large Local Reactions to MRNA Covid-19 Vaccines in Blacks, Indigenous Persons, and People of Color<\/span><\/a><span style=\"font-weight: 400\"> \u2013 New England Journal of Medicine (June 9)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1007\/s10896-021-00290-5\"><span style=\"font-weight: 400\">\u201cThe Stay at Home Order Is Causing Things to Get Heated Up\u201d: Family Conflict Dynamics During COVID-19 From The Perspectives of Youth Calling a National Child Abuse Hotline<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Journal of Family Violence (June)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1177\/00207314211024902\"><span style=\"font-weight: 400\">How Loud and Clear Rung the Alarm Bell: The Communication Efforts of WHO on the Beginning of COVID-19 Outbreak<\/span><\/a><span style=\"font-weight: 400\"> \u2013 International Journal of Health Services: Planning, Administration, Evaluation (June)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1101\/2021.06.11.21258445\"><span style=\"font-weight: 400\">Estimating the Burden of SARS-CoV-2 among the Rohingya Refugees<\/span><\/a><span style=\"font-weight: 400\"> \u2013 MedRxiv (June 14)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1016\/j.xinn.2021.100128\"><span style=\"font-weight: 400\">Assessing the Extent of Community Spread Caused by Mink-Derived SARS-CoV-2 Variants<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Innovation (June)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.12688\/gatesopenres.13210.1\"><span style=\"font-weight: 400\">COVID-19 Vaccine Delivery: An Opportunity to Set up Systems for the Future<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Gates Open Research (2020)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1016\/j.eclinm.2021.100881\"><span style=\"font-weight: 400\">A Media Intervention Applying Debunking versus Non-Debunking Content to Combat Vaccine Misinformation in Elderly in the Netherlands: A Digital Randomised Trial<\/span><\/a><span style=\"font-weight: 400\"> \u2013 EClinicalMedicine (May)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1101\/2021.06.10.21258672\"><span style=\"font-weight: 400\">Reopening International Borders without Quarantine Contact Tracing Integrated Policy against COVID-19<\/span><\/a><span style=\"font-weight: 400\"> \u2013 MedRxiv (June 14)<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><i><span style=\"font-weight: 400\">Report prepared by the UW Alliance for Pandemic Preparedness and Global Health Security and the START Center in collaboration with and on behalf of WA DOH COVID-19 Incident Management Team<\/span><\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The incidence of all-cause mortality among residents of assisted living settings in the US between January and August 2020 was 17% higher compared to the same time period in 2019. Among the 10 states with the highest COVID-19 community spread, during that time period the incidence of all-cause mortality was 24% higher.<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/06\/15\/covid-19-and-telehealth-operations-in-texas-primary-care-clinics-disparities-in-medically-underserved-area-clinics\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":7675,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[5],"tags":[],"topic":[],"class_list":["post-10395","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-covid-19-literature-situation-report"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10395","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=10395"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10395\/revisions"}],"predecessor-version":[{"id":10425,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10395\/revisions\/10425"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media\/7675"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=10395"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=10395"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=10395"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=10395"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}